Autopsy report · NCT04854512

Investigational Study of Delayed Release Metformin

“Strategic company decision - not related to a safety concern”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 675 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 3

Sponsor

Anji Pharma

Sponsor type

Industry

Conditions

Diabetes Mellitus, Type 2

Interventions

Metformin DR; Metformin IR; Metformin DR Placebo; Metformin IR placebo

Participants

675 (planned, not actual)

Sites

87

Countries

Brazil, Bulgaria, Canada, Czechia, Hungary, Poland, Spain, United States

Trials that died the same way

• The KHENERGYC Study
  “Strategic company decision - not related to safety concerns” (99% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (93% match in meaning)
• Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)
  “Strategic business decision (not related to safety or efficacy concerns)” (86% match in meaning)
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
  “Business decision, not related to safety” (84% match in meaning)
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
  “Company decision (not a safety issue)” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.